Definitive Healthcare (NASDAQ:DH) Updates FY 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 0.140-0.170 for the period, compared to the consensus EPS estimate of 0.210. The company issued revenue guidance of $220.0 million-$226.0 million, compared to the consensus revenue estimate of $233.5 million. Definitive Healthcare also updated its Q1 2026 guidance to 0.030-0.030 EPS.

Definitive Healthcare Trading Down 0.7%

NASDAQ:DH traded down $0.01 during trading hours on Thursday, hitting $1.40. The stock had a trading volume of 753,013 shares, compared to its average volume of 372,979. The business’s 50 day moving average is $2.23 and its 200-day moving average is $2.90. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.60 and a current ratio of 1.60. The company has a market cap of $197.91 million, a price-to-earnings ratio of -0.84 and a beta of 1.59. Definitive Healthcare has a one year low of $1.36 and a one year high of $5.22.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.06 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.06. Definitive Healthcare had a negative net margin of 77.88% and a positive return on equity of 3.30%. The company had revenue of $61.53 million for the quarter, compared to analysts’ expectations of $59.57 million. Definitive Healthcare has set its FY 2026 guidance at 0.140-0.170 EPS and its Q1 2026 guidance at 0.030-0.030 EPS. Sell-side analysts anticipate that Definitive Healthcare will post 0.16 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on DH. Wall Street Zen downgraded Definitive Healthcare from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 28th. Morgan Stanley reissued an “underperform” rating and set a $3.50 target price on shares of Definitive Healthcare in a research note on Thursday, December 18th. Canaccord Genuity Group cut their price target on shares of Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Monday, November 10th. Barclays dropped their price objective on shares of Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating on the stock in a report on Monday, December 8th. Finally, William Blair raised shares of Definitive Healthcare to a “strong-buy” rating in a research note on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $3.94.

Hedge Funds Weigh In On Definitive Healthcare

Large investors have recently modified their holdings of the business. Goldman Sachs Group Inc. increased its position in shares of Definitive Healthcare by 564.2% in the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after acquiring an additional 7,404,363 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Definitive Healthcare by 1.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,073,197 shares of the company’s stock worth $8,417,000 after purchasing an additional 33,612 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Definitive Healthcare by 11.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,216,007 shares of the company’s stock valued at $4,937,000 after buying an additional 127,055 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Definitive Healthcare by 23.7% in the second quarter. Bank of America Corp DE now owns 769,397 shares of the company’s stock valued at $3,001,000 after buying an additional 147,599 shares in the last quarter. Finally, Inspire Investing LLC increased its holdings in Definitive Healthcare by 505.7% during the fourth quarter. Inspire Investing LLC now owns 698,967 shares of the company’s stock worth $2,006,000 after buying an additional 583,562 shares during the last quarter. 98.67% of the stock is currently owned by institutional investors and hedge funds.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.